Previous close | 84.07 |
Open | 83.76 |
Bid | 83.07 x 800 |
Ask | 83.43 x 800 |
Day's range | 82.61 - 83.81 |
52-week range | 57.17 - 89.74 |
Volume | |
Avg. volume | 7,858,463 |
Market cap | 104.88B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | 31.67 |
EPS (TTM) | 2.64 |
Earnings date | 02 Feb 2023 |
Forward dividend & yield | 2.92 (3.49%) |
Ex-dividend date | 14 Dec 2022 |
1y target est | 86.33 |
Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend. Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration. With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue.